PURPOSE: This systematic review aims to examine the prevalence of bisphosphonate osteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues. METHODS: A search of MEDLINE/PubMed and EMBASE form October 2003 to December 31, 2008 was conducted with the objective of identifying publications that contained original data regarding BON. RESULTS: A total of 28 publications fulfilled inclusion criteria, but only 22 were used for prevalence analysis. No randomized controlled clinical trials, meta-analysis, or quality of life papers were found that contained information regarding either prevalence or treatment protocols for the management of BON. The overall weighted prevalence of BON included a sample of 39,124 patients with a mean weighted prevalence of 6.1%. The weighted prevalence was 13.3% for studies with documented follow-up with a sample size of 927 individuals. The weighted prevalence in studies with undocumented follow-up was 0.7% in a sample of 8,829 chart reviews. Epidemiological studies evaluated a total of 29,368 individual records, and the weighted BON prevalence was 1.2%. CONCLUSIONS: High-quality studies are needed to accurately characterize the prevalence of BON, and to determine effective treatment protocols.
PURPOSE: This systematic review aims to examine the prevalence of bisphosphonateosteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues. METHODS: A search of MEDLINE/PubMed and EMBASE form October 2003 to December 31, 2008 was conducted with the objective of identifying publications that contained original data regarding BON. RESULTS: A total of 28 publications fulfilled inclusion criteria, but only 22 were used for prevalence analysis. No randomized controlled clinical trials, meta-analysis, or quality of life papers were found that contained information regarding either prevalence or treatment protocols for the management of BON. The overall weighted prevalence of BON included a sample of 39,124 patients with a mean weighted prevalence of 6.1%. The weighted prevalence was 13.3% for studies with documented follow-up with a sample size of 927 individuals. The weighted prevalence in studies with undocumented follow-up was 0.7% in a sample of 8,829 chart reviews. Epidemiological studies evaluated a total of 29,368 individual records, and the weighted BON prevalence was 1.2%. CONCLUSIONS: High-quality studies are needed to accurately characterize the prevalence of BON, and to determine effective treatment protocols.
Authors: Jeanny B Aragon-Ching; Yang-Min Ning; Clara C Chen; Lea Latham; Jean-Pierre Guadagnini; James L Gulley; Philip M Arlen; John J Wright; Howard Parnes; William D Figg; William L Dahut Journal: Cancer Invest Date: 2009-02 Impact factor: 2.176
Authors: Estee P Wang; Leonard B Kaban; Gordon J Strewler; Noopur Raje; Maria J Troulis Journal: J Oral Maxillofac Surg Date: 2007-07 Impact factor: 1.895
Authors: M A Dimopoulos; E Kastritis; C Bamia; I Melakopoulos; D Gika; M Roussou; M Migkou; E Eleftherakis-Papaiakovou; D Christoulas; E Terpos; A Bamias Journal: Ann Oncol Date: 2008-08-09 Impact factor: 32.976
Authors: Rana R McKay; Xun Lin; Julia J Perkins; Daniel Y C Heng; Ronit Simantov; Toni K Choueiri Journal: Eur Urol Date: 2014-02-26 Impact factor: 20.096
Authors: T Van den Wyngaert; M Delforge; C Doyen; L Duck; K Wouters; I Delabaye; C Wouters; H Wildiers Journal: Support Care Cancer Date: 2013-08-18 Impact factor: 3.603
Authors: Fernanda Gonçalves Basso; Taisa N Pansani; Diana G Soares; Lais M Cardoso; Josimeri Hebling; Carlos Alberto de Souza Costa Journal: Clin Oral Investig Date: 2017-07-08 Impact factor: 3.573
Authors: Fernanda Gonçalves Basso; Ana Paula Silveira Turrioni; Diana Gabiela Soares; Vanderlei Salvador Bagnato; Josimeri Hebling; Carlos Alberto de Souza Costa Journal: Support Care Cancer Date: 2014-05-07 Impact factor: 3.603
Authors: Akanksha Srivastava; Graciela M Nogueras Gonzalez; Yimin Geng; Alexander M Won; Maria E Cabanillas; Aung Naing; Jeffrey N Myers; Yisheng Li; Mark S Chambers Journal: Support Care Cancer Date: 2020-11-15 Impact factor: 3.603